DNA Script (South San Francisco, California) has launched its next-generation SYNTAX system, which it describes as “the world’s first DNA printer powered by enzymatic DNA Synthesis (EDS).”
The company recently announced that the SYNTAX system now offers support for q/dPCR assays, supporting same-day results.
DNA Script describes the offering as the first to offer a same-day turnaround for custom q/dPCR assays with a new generation of kits for the SYNTAX system. The system can design and print q/dPCR assays in as little as 8 hours.
“Since we released the world’s first commercial access to Enzymatic DNA Synthesis via the SYNTAX platform in the summer of 2021, we have made a number of improvements to advance benchtop DNA printing,” said Thomas Ybert, DNA Script co-founder and CEO, in a statement. “Given the many applications, and the urgent need to perform them quickly, in-house DNA printing on demand is becoming one of the most important technologies of the 21st century.”
The printer can be used for various applications, including creating DNA or mRNA vaccines against new pathogens while generally accelerating the development of RNA-based therapies. The SYNTAX platform also supports fast detection of pathogenic biothreats as well as biomarker identification and gene expression profiling. Finally, the printer can also be used to create a DNA-based data storage system, given the sizable amounts of digital data it generates.
DNA Script that the new kits provide a variety of new capabilities to the Syntax platform. Namely, it can print oligos up to 80 nt in length and synthesize hydrolysis probes and primers in the same run. Additionally, it can print oligos at a higher yield and concentration than before.
[Image courtesy of DNA Script]
Filed Under: Cell & gene therapy, Drug Discovery, Drug Discovery and Development
